Iovance earnings for the third quarter of 2026 are scheduled to be reported on November 5, when the biotechnology company will also provide corporate updates on a conference call and live audio webcast.

Key Takeaways

  • The call is scheduled for 8:30 a.m. Eastern Time.
  • An archived webcast will be available for one year.

Iovance earnings webcast details

Iovance Biotherapeutics announced the schedule on October 27. The company did not disclose third-quarter financial results in the announcement.

Listeners can register for the live or archived audio webcast. Both will be accessible through the investors section of the company’s website.

Cancer therapy business

Iovance develops tumor infiltrating lymphocyte, or TIL, cell therapies for cancer. Its Amtagvi treatment is approved for previously treated advanced melanoma, and the company says it is available at nearly 100 authorized treatment centers.

The company also has clinical and next-generation programs targeting other solid tumors.

Read More News

More FinanceVelix news

Disclaimer

This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.